好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The Role of Discrimination on Migraine Disease Burden in African Americans
Headache
P3 - Poster Session 3 (11:45 AM-12:45 PM)
12-005

This study investigated the relationship between headache frequency, perceived discrimination (lifetime and in a medical setting), and migraine-specific quality of life among an African American (AA) sample.

Widespread disparities in migraine care exist by race/ethnicity, leading to poorer health outcomes in minoritized populations. AA are particularly affected and are less likely to seek healthcare for migraine.

Self-identified AA with an ICD-10 diagnosis of migraine, seen at a tertiary headache center within the last 12 months, were recruited via telephone and email to participate in a one-time online survey. Data collection included Item A of the Migraine Disability Assessment (MIDAS-A), the Migraine-Specific Quality of Life Questionnaire (MSQ) v2.1, the Brief Perceived Ethnic Discrimination Questionnaire-Community Version (PEDQ-CV), and the Discrimination in Medical Settings (DMS) Scale. Pearson correlations evaluated bivariate relationships among variables.

Ninety-one individuals (94.5% female, 5.5% male), all identifying as Black and/or AA (72.5% Non-Hispanic, 27.5% Hispanic), ages 18 to 78 years (M = 38.49, SD = 12.58) participated. Higher levels of discrimination in medical settings were associated with increased headache days (MIDAS-A: r = 0.26, p < .05), while lifetime discrimination showed a weak non-significant association (r = 0.07, p > .05). Significant negative associations were observed between the PEDQ-CV and MSQ subscales: Role Function Restrictive (r = -.27, p < .05) and Emotional Function (r = -.23, p < .05). Meanwhile, DMS scores negatively associated with all MSQ subscales Role Function Restrictive (r = -0.28, p < .01), Role Function Prevention (r = -.23, p < .05), and Emotional Function (r = -0.23, p < .05).

Discrimination, particularly in medical settings, is associated with increased headache frequency and decreased migraine-specific quality of life in AA with migraine. Addressing discrimination may help to build trust, encourage migraine care-seeking, and reduce disparities in AA patients with migraine.

Authors/Disclosures
Mara Getz, MPH
PRESENTER
Ms. Getz has nothing to disclose.
Larry "LC" Charleston IV, MD, MSc, FAHS, FANA, FAAN (A NeuRaye Of Sunshine Publishing, LLC) Dr. Charleston has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AbbVie. Dr. Charleston has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amneal Pharmaceuticals. Dr. Charleston has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma Pharmaceuticals. Dr. Charleston has received personal compensation in the range of $500-$4,999 for serving as a Consultant for LinPharma. Dr. Charleston has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Haleon. Dr. Charleston has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Pfizer. The institution of Dr. Charleston has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Axsome. Dr. Charleston has or had stock in Mi-Helper Inc..Dr. Charleston has a non-compensated relationship as a Associate Editor with Headache Journal: The Journal of Head and Face Pain that is relevant to AAN interests or activities. Dr. Charleston has a non-compensated relationship as a Board Member with Clinical Neurological Society of America that is relevant to AAN interests or activities. Dr. Charleston has a non-compensated relationship as a Chair, EDI Advisory Committee (Non-voting Board Member) with American Headache Society that is relevant to AAN interests or activities.
Cynthia E. Armand, MD, FAAN (Montefiore Medical Headache Center) Dr. Armand has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CE Interactive. Dr. Armand has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Armand has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. Dr. Armand has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Neurology.
Elizabeth Seng, PhD (Yeshiva University, Albert Einstein College of Medicine) Dr. Seng has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbvie. Dr. Seng has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Theranica. Dr. Seng has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. The institution of Dr. Seng has received research support from NCCIH. Dr. Seng has received research support from Cystic Fibrosis Foundation. The institution of Dr. Seng has received research support from American Heart Association.